A Pharmacokinetic & Pharmacodynamic Study of Oral Lenalidomide in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes

被引:0
作者
Wu, Anfan
List, Alan
Lush, Richard
Bretz, Kelly
Knight, Robert
Lau, Henry
Zeldis, Jerry
机构
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
4854
引用
收藏
页码:299B / 299B
页数:1
相关论文
共 50 条
  • [41] Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review
    Park, Sophie
    Greenberg, Peter
    Yucel, Aylin
    Farmer, Caroline
    O'Neill, Frank
    Brandao, Cisio De Oliveira
    Fenaux, Pierre
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (02) : 134 - 160
  • [42] Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis
    Kuendgen, A.
    Lauseker, M.
    List, A. F.
    Fenaux, P.
    Giagounidis, A. A.
    Brandenburg, N. A.
    Backstrom, J.
    Glasmacher, A.
    Hasford, J.
    Germing, U.
    LEUKEMIA, 2013, 27 (05) : 1072 - 1079
  • [43] Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis
    A Kuendgen
    M Lauseker
    A F List
    P Fenaux
    A A Giagounidis
    N A Brandenburg
    J Backstrom
    A Glasmacher
    J Hasford
    U Germing
    Leukemia, 2013, 27 : 1072 - 1079
  • [44] A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome
    Komrokji, Rami S.
    Carraway, Hetty E.
    Germing, Ulrich
    Wermke, Martin
    Zeidan, Amer M.
    Fu, Eric
    Rueter, Bjoern
    Burkard, Ute
    Osswald, Annika
    Foran, James M.
    HAEMATOLOGICA, 2022, 107 (11) : 2742 - 2747
  • [45] A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome
    Komrokji, Rami S.
    Carraway, Hetty E.
    Germing, Ulrich
    Wermke, Martin
    Zeidan, Amer M.
    Fu, Eric
    Rueter, Bjoern
    Burkard, Ute
    Osswald, Annika
    Foran, James M.
    HAEMATOLOGICA, 2022, 107 : 2742 - 2747
  • [46] LENALIDOMIDE THERAPY IN MYELODYSPLASTIC SYNDROMES WITH LOW-OR-INTERMEDIATE-1 IPSS RISK AND DEL(5Q): RETROSPECTIVE STUDY OF 17 PATIENTS FROM A SINGLE INSTITUTION
    Finelli, C.
    Follo, M. Y.
    Barraco, M.
    De Maio, C.
    Testoni, N.
    Ottaviani, E.
    Parisi, S.
    Mongiorgi, S.
    Stanzani, M.
    Papayannidis, C.
    Cocco, L.
    Cavo, M.
    HAEMATOLOGICA, 2016, 101 : S119 - S119
  • [47] Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes
    Garcia-Manero, Guillermo
    Diez-Campelo, Maria
    Vellenga, Edo
    Jacoby, Meagan A.
    Merchan, Brayan
    Breems, Dimitri
    Cortelezzi, Agostino
    Doronin, Vadim
    Gomez, Valle
    Beckers, Marielle
    Della Porta, Matteo Giovanni
    Varsos, Helen
    Xiu, Liang
    DeAngelis, Nikki
    Nnane, Ivo
    Rose, Esther
    van Eygen, Koen
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (04) : E111 - E114
  • [48] p53 protein expression predicts outcome and cytogenetic response in patients with low-/INT-1-risk myelodysplastic syndromes treated with lenalidomide
    Saft, L.
    Karimi, M.
    Ghaderi, M.
    Matolscy, A.
    Fenaux, P.
    Mufti, G.
    Giagounidis, A.
    Selleslag, D.
    Muus, P.
    Sanz, G.
    Mittelman, M.
    Bowen, D.
    Porwit, A.
    Fu, T.
    Backstrom, J.
    MacBeth, K.
    Hellstrom-Lindberg, E.
    LEUKEMIA RESEARCH, 2013, 37 : S66 - S66
  • [49] Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial
    Gonzalez-Lugo, Jesus D.
    Kambhampati, Suman
    Yacoub, Abdulraheem
    Donnellan, William B.
    Berdeja, Jesus
    Bhagat, Prafulla
    Fehn, Karen
    Remy, Cassady
    Jasra, Sakshi
    Kazemi, Mohammed
    Pradhan, Kith
    Kim, Mimi
    Mantzaris, Ioannis
    Sica, R. Alejandro
    Shah, Nishi
    Goldfinger, Mendel
    Kornblum, Noah
    Gritsman, Kira
    Braunschweig, Ira
    Steidl, Ulrich
    Will, Britta
    Shastri, Aditi
    Verma, Amit
    CLINICAL CANCER RESEARCH, 2023, 29 (01) : 60 - 66
  • [50] A Prospective Multicenter Open-Label Study of the Effectiveness of Epoetin Beta for Patients with Low/Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Preliminary Result
    Chuncharunee, Suporn
    Kanitsap, Nonglak
    Suwanban, Tawatchai
    Khuhapinant, Archrob
    Uaprasert, Noppacharn
    Chansung, Kanchana
    Rattarittamrong, Ekarat
    Wongkhantee, Somchai
    Siritanaratanakul, Noppadol
    Norasetthada, Lalita
    Nakorn, Thanyaphong Na
    Charnwiboonsri, Chadchai
    BLOOD, 2016, 128 (22)